Back to Search Start Over

Phase II Trial of Tandem High-Dose Chemotherapy with Autologous Stem Cell Transplantation Followed by Reduced-Intensity Allogeneic Stem Cell Transplantation for Patients with High-Risk Lymphoma

Authors :
Jessica Driscoll
Ronald W. Takvorian
Thomas R. Spitzer
Ephraim P. Hochberg
Yi Bin Chen
Corey Cutler
Vincent T. Ho
Jennifer R. Brown
David C. Fisher
Jeremy S. Abramson
Eric D. Jacobsen
Steven L. McAfee
Jeffrey A. Barnes
Robert J. Soiffer
Philippe Armand
Shuli Li
Candice Del Rio
Areej El-Jawahri
Joseph H. Antin
Source :
Biology of Blood and Marrow Transplantation. 21(9):1583-1588
Publication Year :
2015
Publisher :
Elsevier BV, 2015.

Abstract

Many patients with lymphoma relapse after autologous stem cell transplantation (AutoSCT). These patients are often considered for allogeneic stem cell transplantation (AlloSCT) if remission can be achieved. If a tandem approach was organized, some cases of relapse might be prevented. We conducted a phase II trial of tandem AutoSCT followed by reduced-intensity conditioning (RIC) AlloSCT for patients with high-risk lymphoma. High-dose chemotherapy was given with busulfan, cyclophosphamide, and etoposide. AlloSCT was composed of RIC with busulfan/fludarabine and tacrolimus, sirolimus, and methotrexate as graft-versus-host disease (GVHD) prophylaxis. Donors were fully matched related or unrelated donors. AlloSCT was performed any time between 40 days and 6 months after AutoSCT. Forty-two patients were enrolled, and all patients underwent AutoSCT. RIC AlloSCT was performed in 29 patients. In the 29 patients who underwent tandem transplant, median time from AutoSCT to AlloSCT was 96 days (range, 48 to 169). The 6-month cumulative incidence of grades II to IV acute GVHD was 13.8% (90% confidence interval [CI], 5.3% to 26.3%). Cumulative incidence of chronic GVHD at 1 year was 37.9% (90% CI, 23.1% to 52.7%). Nonrelapse mortality at 2 years after AlloSCT was 11.1% (90% CI, 3.5% to 23.6%). At a median follow-up of 30 months (range, 17.1 to 51.5) for the entire group, the 2-year progression-free survival rate was 64% (90% CI, 50% to 75%) and the 2-year overall survival rate was 69% (90% CI, 43% to 85%). For the 29 patients who underwent tandem SCT, the 2-year progression-free survival rate was 72% (90% CI, 55% to 83%) and the 2-year OS rate was 89% (90% CI, 74% to 96%). Tandem AutoSCT–RIC AlloSCT appears to be safe and effective in patients with high-risk lymphoma. Prospective trials using such an approach in specific lymphoma subtypes are warranted.

Details

ISSN :
10838791
Volume :
21
Issue :
9
Database :
OpenAIRE
Journal :
Biology of Blood and Marrow Transplantation
Accession number :
edsair.doi.dedup.....585c22314337fc21b33b2cdb4fcd62a2
Full Text :
https://doi.org/10.1016/j.bbmt.2015.05.016